EMEA-002066-PIP02-20

Key facts

Invented name
Talzenna
Active substance
talazoparib
Therapeutic area
Oncology
Decision number
P/130/2021
PIP number
EMEA-002066-PIP02-20
Pharmaceutical form(s)
  • Capsule, hard
  • Capsule, soft
Condition(s) / indication(s)
  • Treatment of breast malignant neoplasms
  • Treatment of prostate malignant neoplasms
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europe MA EEIG

Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating